ORGANIC COMPOSITIONS TO TREAT BETA-ENAC-RELATED DISEASES
Publication
EP3431604A1
Kind: A1
Mar 18, 2026
Applicants
Arrowhead Pharmaceuticals, Inc.
Inventors
DE FOUGEROLLES, Antonin, DIENER, John L., HICKMAN, Emma, HINKLE, Gregory, MILSTEIN, Stuart, PULICHINO, Anne-Marie, SPRAGUE, Andrew
Abstract
The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
IPC Classifications
C12N 15/113 20100101AFI20181109BHEP
A61P 3/12 20060101ALI20181109BHEP
A61K 31/713 20060101ALI20181109BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR